Skip to main content

FDA recall, , Moderate risk

Huons Lidocaine, Bupivacaine and Sodium Chloride Injections

Lidocaine HCl injection lacks assurance of sterility.

What happened

Huons Co., Ltd., of Jecheon, Korea, recalled multiple injectable products due to a lack of assurance of sterility. The recall began April 2, 2026, and was added to the FDA's Enforcement Report on April 14, 2026. The products were distributed nationwide in the USA.

What to do

We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:

  1. Check the FDA or company notice for instructions specific to this product.
  2. Ask your pharmacist or doctor whether your lot is affected and what to do.

Is yours affected?

4 products

Compare the details below with your product and check the FDA notice to confirm whether it is affected.

An NDC (National Drug Code) is usually printed on the drug's label.

  1. Bupivacaine Hydrochloride 0.75% in 8.25% Dextrose Injection, USP (

    Strength
    15 mg
    NDC
    • 73293-0002-1
    • 73293-0002-2
    • 71351-022-02
    • 71351-022-10
    • 71351-022-50
    Lot code
    All lots within expiry
  2. 0.9% Sodium Chloride Injection, USP, 10 mL Ampules, Rx only, Single Dose, Preservative Free

    NDC
    • 65282-1510-1
    Lot code
    All lots within expiry
  3. Lidocaine HCl injection, USP, 1%

    Strength
    50 mg
    NDC
    • 73293-0001-1
    • 73293-0001-2
    • 63739-170-13
    • 63739-170-24
    • 63739-170-27
    • 71351-021-05
    • 71351-021-10
    • 71351-021-25
    • 84769-0001-1
    • 84769-0001-2
    Lot code
    All lots within expiry
  4. Lidocaine HCl Injection, USP, 2%

    Strength
    100 mg
    NDC
    • 73293-0003-1
    • 73293-0003-2
    • 71351-023-05
    • 71351-023-10
    • 71351-023-25
    • 68094-081-01
    • 68094-081-25
    • 84769-0002-1
    • 84769-0002-2
    Lot code
    All lots within expiry

Recall details

Company began the recall
Sold in

USA Nationwide.

Company
Huons Co., Ltd.Jecheon, Korea (the Republic of)
Risk

Moderate risk

Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.

FDA Class II recall · How risk is rated

Event ID
98724
Recall numbers
D-0529-2026 to D-0532-2026

Timeline

FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.

  1. Company began the recall

  2. Added to FDA's Enforcement Report

  3. In FDA's weekly enforcement report

  4. Listed on Recall Canary

  5. Classified by FDA

  6. Summary updated

Summary by Recall Canary, written with AI · summary updated Oct 3, 2026 · primary source: U.S. Food and Drug Administration (opens in a new tab)